Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin

NCT00701935 on ClinicalTrials.gov · last registry update 2015-04-10

Stopped early, having planned 80 participants. The sponsor logged completion for January 2012. Primary outcome, as filed: Percentage Change in Abdominal Visceral Fat From Baseline to 6 Months. exenatide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: TERMINATED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 80
Started: 2008-08
Primary completion: 2012-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage Change in Abdominal Visceral Fat From Baseline to 6 Months

Conditions studied

Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.